樂
樂觀
樂觀 · 25%LENZ
$37.95
情境價格
$3.010
-0.392 (-13.01%)收盤時
Loading chart…
- 最高
- 3.440
- 開盤
- 3.440
- 成交量加權均價
- 3.15
- 成交量
- 737.00K
- 市值
- —
- 最低
- 3.000
- 成交金額
- 2.32M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- -0.23
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
AI 分析 of LENZ Therapeutics Inc (LENZ)
買進LENZ Therapeutics Inc is a good buy right now at a current price of $3.05, especially considering its recent sales growth of 50% in Q3 2026, which indicates increasing market acceptance. The stock is currently oversold with an RSI of 36.13, suggesting potential for a rebound. However, the main risk is its significant year-to-date decline of 80.94%, which highlights volatility and uncertainty in the stock's recovery.
估值指標
LENZ Therapeutics Inc（LENZ）目前預期本益比為 0.00，5 年平均預期本益比為 -10.36。
Alphio AI 對 LENZ 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
持有 LENZ 的大戶
事件時間軸
資訊
8.510-28NewsfilterLENZ Therapeutics Reports 50% Q3 Sales Growth and Strategic Reorganization
2.007-14NASDAQ.COMLenz Therapeutics Shares Enter Oversold Territory
- 8.507-06Newsfilter
LENZ Launches Telehealth Platform for VIZZ
- 7.506-24Newsfilter
LENZ and Arrotex Sign Exclusive License Agreement for VIZZ in Australia and New Zealand
8.506-12NASDAQ.COMBiotech Sector Sees Surge in FDA and Global Approvals
LENZ 常見問題 —— 由 Alphio AI 解答
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
LENZ Therapeutics Inc is a good buy right now at a current price of $3.05, especially considering its recent sales growth of 50% in Q3 2026, which indicates increasing market acceptance. The stock is currently oversold with an RSI of 36.13, suggesting potential for a rebound. However, the main risk is its significant year-to-date decline of 80.94%, which highlights volatility and uncertainty in the stock's recovery.
社群
更多 ↗
$LENZ: LENZ Theutics approves reorganization, cutting 75% of staff and targeting over 50% lower 2027 operating expenses.
展開相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。